{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "35075281",
  "DateCompleted": {
    "Year": "2022",
    "Month": "02",
    "Day": "10"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "02",
    "Day": "15"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1038/s41590-021-01116-8"
    ],
    "Journal": {
      "ISSN": "1529-2916",
      "JournalIssue": {
        "Volume": "23",
        "Issue": "2",
        "PubDate": {
          "Year": "2022",
          "Month": "Feb"
        }
      },
      "Title": "Nature immunology",
      "ISOAbbreviation": "Nat Immunol"
    },
    "ArticleTitle": "COVID-19 vaccine trials must include helminth-infected cohorts.",
    "Pagination": {
      "StartPage": "148",
      "MedlinePgn": "148"
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0001-8191-0898"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Med Biotech Laboratories, Kampala, Uganda. tgegwang@gmail.com."
          }
        ],
        "LastName": "Egwang",
        "ForeName": "Thomas G",
        "Initials": "TG"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Med Biotech Laboratories, Kampala, Uganda."
          }
        ],
        "LastName": "Owalla",
        "ForeName": "Tonny Jimmy",
        "Initials": "TJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Kiruddu Referral Hospital, Kampala, Uganda."
          }
        ],
        "LastName": "Kemigisha",
        "ForeName": "Margaret",
        "Initials": "M"
      }
    ],
    "PublicationTypeList": [
      "Letter"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Nat Immunol",
    "NlmUniqueID": "100941354",
    "ISSNLinking": "1529-2908"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "epidemiology"
      ],
      "DescriptorName": "Africa"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "epidemiology",
        "immunology",
        "prevention & control",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects"
      ],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Clinical Trials as Topic"
    },
    {
      "QualifierName": [
        "epidemiology",
        "immunology",
        "parasitology"
      ],
      "DescriptorName": "Helminthiasis"
    },
    {
      "QualifierName": [
        "immunology",
        "pathogenicity"
      ],
      "DescriptorName": "Helminths"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Host-Pathogen Interactions"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Immunization Schedule"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Research Design"
    },
    {
      "QualifierName": [
        "immunology",
        "pathogenicity"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Vaccination"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Vaccine Development"
    }
  ]
}